Cyclic and branch cyclic peptides (cyclopeptides) represent an important class of bioactive natural products that include many antibiotics and anti-tumor compounds. However, little is known about cyclopeptides in the human gut, despite the fact that humans are constantly exposed to them. To address this bottleneck, we developed the CycloNovo algorithm for de novo cyclopeptide sequencing that employs de Bruijn graphs, the workhorse of DNA sequencing algorithms. CycloNovo reconstructed many new cyclopeptides that we validated with transcriptome, metagenome, and genome mining analyses. Our benchmarking revealed a vast hidden cyclopeptidome in the human gut and other environments and suggested that CycloNovo offers a much-needed stepchange for cyclopeptide discovery. Furthermore, CycloNovo revealed a wealth of antimicrobial cyclopeptides from food that survive the complete human gastrointestinal tract, raising the question of how these cyclopeptides might affect the human microbiome.
INTRODUCTION
The golden age of antibiotics was followed by a decline in the pace of antibiotics discovery in the 1990s. However, antibiotics and other natural products are again at the center of attention as exemplified by the recent discovery of teixobactin 1 . The key prerequisite for the resurgence of antibiotics research is the development of computational discovery pipelines 2 such as the Global Natural Products Social (GNPS) molecular networking 3 , Dereplicator 4 , and VarQuest 5 . The GNPS project already accumulated over a billion mass spectra, an untapped resource for discovery of new antibiotics. However, new algorithms are needed for the GNPS project to realize its promise for antibiotics discovery. Currently, the GNPS network is mainly used for identification of previously discovered natural products and their analogs, emphasizing the need for algorithms for discovery of novel natural products.
This study focuses on cyclopeptides, an important class of bioactive natural products with an unparalleled track record in pharmacology: many antibiotics as well as anti-tumor agents, immunosuppressors, and toxins are cyclopeptides. Cyclopeptide sequencing from tandem mass spectra is challenging as their propensity to break at all pairs of points in their cyclic backbone gives a far more complex series of ions than in linear peptides. Cyclopeptides are divided into cyclic Non-Ribosomal Peptides (NRPs) and cyclic Ribosomally synthesized and Posttranslationally modified Peptides (RiPPs). NRPs are built from 300 different naturally occurring amino acids according to the complex nonribosomal code 6 rather than the genetic code. RiPPs are encoded using the genetic code and so built from the twenty proteinogenic amino acids, which however are subjected to numerous post-translational modifications.
The discovery of the cyclopeptide gramicidin S in 1942 (first antibiotic used for treating soldiers during the World War II) led to two Nobel prizes and has been followed by the discovery of ≈400 families of cyclopeptides (cyclofamilies) in the last 75 years 5 . A relatively small number of known cyclofamilies reflects the experimental and computational challenges in cyclopeptide discovery. Moreover, the question of how many cyclofamilies remained below the radar of previous studies (even though their spectra have already been deposited to public databases!) remains open.
To answer this question, we consider the problem of recognizing cyclospectra (tandem mass spectra that originated from cyclopeptides) that can be matched against biosynthetic genes using various genome mining and peptidogenomics tools 7, 8 . These tools typically generate a huge database of putative cyclopeptides, making it prohibitively timeconsuming to search large spectral datasets against such databases. Fast algorithms for recognizing cyclospectra are critical for genome mining as they greatly reduce the set of spectra that need to be matched against databases of putative cyclopeptides.
Bandeira et al. 9 introduced the concept of spectral networks that reveal the spectra of related peptides without knowing their amino acid sequences. Nodes in a spectral network correspond to spectra while edges connect spectral pairs, i.e. spectra of peptides differing by a single modification or a mutation (see Supplementary Note "Surugamide spectral network.") Ideally, each connected component of a spectral network corresponds to a cyclofamily 10 representing a set of similar cyclopeptides. Although spectral networks of various GNPS datasets have become the workhorse of the cyclopeptide studies, they typically contain false positive edges that make analysis of cyclofamilies challenging 3 . Moreover, constructing the spectral network of all GNPS spectra remains an open algorithmic problem.
Recognition of cyclospectra creates a possibility to construct a small cyclospectral subnetwork of the entire GNPS network and to evaluate the number of cyclofamilies in the GNPS network as the number of connected components in this sub-network. This analysis revealed that many cyclopeptides evaded detection in previous studies and that the known cyclopeptides represent the tip of the iceberg of cyclopeptides that are waiting to be decoded from the GNPS network.
We distinguish between cyclopeptide identification (identifying cyclopeptides by matching their spectra against databases of known cyclopeptides 11 ) and de novo cyclopeptide sequencing (determining the cyclopeptide sequence from a spectrum alone). Although recent studies have made progress towards cyclopeptide identification 4, 5, 12, 13 , the previously developed cyclopeptide sequencing algorithms [14] [15] [16] [17] are rarely used 11 because they are rather inaccurate, too slow for analyzing high-throughput spectral datasets, and cannot distinguish cyclopeptides from other compounds.
Here we describe CycloNovo, a fast cyclopeptide sequencing algorithm based on the concept of the de Bruijn graph of a spectrum, a compact representation of putative k-mers (strings formed by k consecutive amino acids) in an unknown cyclopeptide (see Supplementary Note "An example of the de Bruijn graph.") Although de Bruijn graphs represent the workhorse of DNA sequencing 18 , they have not previously been applied to cyclopeptide sequencing. We demonstrate that CycloNovo enables high-throughput analysis of cyclopeptides in large spectral datasets and sequence many cyclopeptides in diverse samples that include marine, soil, and human gut bacterial communities.
RESULTS
To illustrate how CycloNovo works, we used a spectrum of the cyclopeptide surugamide A 19 (referred to as surugamide hereon) with the amino acid sequence AIIKIFLI ( Figure 1 ). Each chord corresponds to a fragment of surugamide. The solid chords represent the fragments in TheoreticalSpectrum(Surugamide) whose masses match masses in the experimental spectrum SpectrumSurugamide. The numbers on solid chords show the nominal masses of the corresponding fragment, e.g., the chord labeled 297 corresponds to the fragment Ile-Ile-Ala of mass 297 Da. Each chord corresponds either to a single mass x or two masses x and mass(Spectrum)-x (in the latter case the chord is shown in bold). Given a set of fragments with the same mass, we show one of them (arbitrarily chosen) by a solid chord and the others by dashed chords. For example, one of two fragments with the same integer mass 241 (Ile-Lys and Lys-Ile in clockwise order), is shown by a solid chord and another by a dashed chord. (Top right) The experimental spectrum of surugamide (SpectrumSurugamide) with 82 peaks (GNPS ID MSV000078839). The y-axis in the SpectrumSurugamide shows the ion intensities as the percentage of the intensity of the highest intensity peak. Blue peaks represent masses shared with TheoreticalSpectrum(Surugamide) for the error threshold ε = 0.015 Da. (Bottom) The theoretical and (pre-processed) experimental spectra for surugamide rounded to the nearest integer (this rounding results in the repetitive integers in the list). Masses in the pre-processed experimental spectrum are reduced by the mass of hydrogen mH≈1.0078 Da. A mass in the theoretical spectrum is shared with a mass in the experimental spectrum if they are within the error threshold. The numbers in bold represent 13 shared masses.
Theoretical and experimental spectra. Given an amino acid string, its mass is defined as the sum of masses of its amino acids. Given a cyclopeptide Peptide, its theoretical spectrum TheoreticalSpectrum(Peptide) is the set of masses of all substrings of Peptide ( Figure 1 ). For example, TheoreticalSpectrum(AGCD) contains masses of A, G, C, D, AG, GC, CD, DA, AGC, GCD, CDA, DAG, and AGCD. Note that if multiple fragments have the same mass, they contribute a single mass to the theoretical spectrum.
An experimental spectrum is a list of peaks, where each peak is characterized by its intensity and m/z (m and z represent the mass and the charge of the ion corresponding to the peak). For simplicity, we will represent a pre-processed spectrum as an increasing sequence of numbers Spectrum={s1, …, sn}, assuming that all peaks in the spectrum have charge 1 and ignoring intensities (see Supplementary Note: "Preprocessing spectra.") We estimate the PeptideMass of the cyclopeptide that generated Spectrum based on the precursor mass and the charge of Spectrum. We define the symmetric version of Spectrum (denoted Spectrum*) as a spectrum that, in addition to all masses in Spectrum, contains PeptideMass-s for each mass s in Spectrum.
Scoring Peptide-Spectrum Matches. A mass s in a (pre-processed) experimental spectrum Spectrum matches a mass s' in TheoreticalSpectrum(Peptide) if s is "equal" to s'. By "equal" we mean "approximately equal" with error below the error threshold (all default values are specified in the Supplementary Note "CycloNovo parameters.") The score between Peptide and Spectrum (denoted score(Peptide, Spectrum) is defined as the number of matches between masses in Spectrum and masses in TheoreticalSpectrum(Peptide). Although CycloNovo uses accurate masses, examples below use nominal masses for simplicity. Cyclopeptidic amino acids. Gurevich et al. 5 combined all currently known peptidic natural products into a single PNPDatabase. This database contains 1,257 cyclopeptides (387 cyclofamilies) that we refer to as CyclopeptideDatabase. We formed the set of cyclopeptidic amino acids (i.e., amino acids that occur in many cyclopeptides) by considering 25 most frequent amino acids in cyclopeptides from CyclopeptideDatabase and extending this list to include all proteinogenic amino acids and some common amino acids in RiPPs (see Supplementary Note "Cyclopeptidic amino acids"). 255 out of 1,257 cyclopeptides in the CyclopeptideDatabase include only cyclopeptidic amino acids.
Spectral convolution. The convolution of a spectrum is the set of all pairwise differences between its masses 15 . Given a mass a, the convolution of Spectrum with offset a (denoted convolution (Spectrum, a) ) is defined as the number of masses in the convolution equal to a (with error up to ε). As shown by Ng et al. 15 , the value convolution(Spectrum, a) is expected to be high if a is the mass of an amino acid in a cyclopeptide that gave rise to Spectrum. Thus, offsets with high convolutions reveal the masses of amino acids in an unknown cyclopeptide that gave rise to an experimental spectrum.
To account for measurement errors, we cluster the masses in the convolution using single linkage clustering by combining pairs of masses in a cluster if they are less than apart. We define the cluster mass as the median mass of its members, and cluster multiplicity as the number of elements in the cluster. We call a cluster cyclopeptidic if one of its elements is within of the mass of a cyclopeptidic amino acid. Since high-multiplicity clusters reveal amino acids in the unknown cyclopeptide that gave rise to an experimental spectrum, we use them to generate the set of putative amino acids in an unknown cyclopeptide 15 . See Supplementary Note "Analyzing spectral convolution" for more details.
CycloNovo outline. Given an experimental spectrum Spectrum, the Cyclopeptide Sequencing Problem refers to finding a cyclopeptide Peptide that maximizes score(Peptide, Spectrum). Figure 2 illustrates the CycloNovo pipeline for solving this problem:
• Recognizing cyclospectra. Natural product researchers use Marfey's analysis for inferring the amino acid composition of an unknown peptide. However, since Marfey's analysis requires a purified peptide and has a number of limitations 20 , we describe its in silico alternative for deriving an approximate amino acid composition of a cyclopeptide that gave rise to a given spectrum (see Methods section). If applying this approach reveals that a spectrum originated from a cyclopepeptide, we classify it as a cyclospectrum.
• Predicting amino acids in a cyclopeptide. For each cyclospectrum, CycloNovo predicts the set of putative amino acids in a cyclopeptide that gave rise to this spectrum. CycloNovo considers each cyclopeptidic cluster with multiplicity exceeding the cyclopeptidic aa threshold and classifies the cyclopeptidic amino acids corresponding to this cluster as a putative amino acid of the cyclopeptide that generated the cyclospectrum. Figure 2 illustrates that CycloNovo classifies amino acids A, I/L, F, K, T, W, R, and G as putative amino acids for SpectrumSurugamide (amino acids occurring in suragamide are shown in bold).
• Predicting amino acid composition of a cyclopeptide. For each cyclospectrum, CycloNovo uses dynamic programming to find all combinations of putative amino acids with total mass matching the precursor mass of the spectrum. We refer to each such combination as putative composition Composition(Spectrum), which may include the same amino acid multiple times. Figure 2 Figure 2 illustrates that three out of six highest scoring 5-mers for SpectrumSurugamide are correct, i.e., represent 5-mers from surugamide. CycloNovo computes the k-merScore, the score of the highestscoring k-mer.
• Constructing the de Bruijn graph of a spectrum. Given a set Kmers= KmersComposition,k(Spectrum), CycloNovo constructs the de Bruijn graph DBKmers(Spectrum) 18 . Nodes in DBKmers(Spectrum) correspond to all (k-1)-mers from Kmers and each directed edge corresponds to a k-mer from Kmers and connects its first (k-1)-mer with its last (k-1)-mer. Each cycle in DBKmers(Spectrum) spells out a cyclic amino acid sequence. Figure 2 (Figure 2 ).
• Generating cyclopeptide reconstructions. A cycle in the de Bruijn graph of a spectrum is feasible if it spells a cyclopeptide with the mass matching the precursor mass of the spectrum. Using the breadth-first search algorithm, CycloNovo finds all feasible cycles in the de Bruijn graph with length equal to the number of amino acids in Composition (a cycle may traverse the same edge multiple times). Each such cycle spells a putative cyclopeptide and CycloNovo scores each of them against Spectrum. Finally, it reports the highest scoring cyclopeptides along with the P-values of their Peptide-Spectrum Matches (PSMs) computed using MS-DPR 21 . (1) recognizing cyclospectra, (2) predicting amino acids in a cyclopeptide, (3) predicting amino acid composition of a cyclopeptide, (4), predicting k-mers in a cyclopeptide, (5) constructing the de Bruijn graph of a spectrum, and (6) Datasets. We analyzed various spectral datasets obtained from diverse bacterial communities (Table 1 and Supplementary Note "Information about spectral datasets"). To benchmark CycloNovo, we also analyzed a plant spectral dataset that had a paired RNAseq dataset, thus enabling us to validate the CycloNovo reconstructions by matching them against the transcriptome.
The CYCLOLIBRARY dataset contains 81 spectra from 81 distinct cyclopeptides (forming 41 cyclofamilies) that were identified by Dereplicator 4 after searching the GNPS network against CyclopeptideDatabase 5 .
The S.VULGARIS dataset is generated from a single sample collected from seeds of the plant Senecio vulgaris (both medicinal and poisonous) 22 from the Asteraceae family. We also analyzed the RNA-Seq reads from the same sample (~74 million 100 bp long Illumina reads) 22 , assembled them using rnaSPAdes 23 , and used the assembled transcripts (61.9 Mb total length) and prior knowledge of cyclopeptide processing [24] [25] [26] to validate the reconstructed cyclopeptides.
The HUMANSTOOL dataset is generated from 65 stool samples of a single person (L.S., co-author of this paper and a contributor to the "Quantified self" initiative) collected over a course of four years. This dataset is accompanied by the detailed medical and food metadata 27 as well as metagenomics reads generated from the same samples (project ID PRJEB24161).
The GNPS dataset is formed by combining forty datasets from GNPS 3 . The GNPSCYANO, GNPSPSEUDO, and GNPSACTI datasets represent sub-datasets of the GNPS dataset corresponding to three phyla with extensively analyzed cyclopeptides (Cyanobacteria, Pseudomonas and Actinomyces). Analyzing the CYCLOLIBRARY dataset. As the cyclopeptides that gave rise to the spectra in the CYCLOLIBRARY dataset are known, we used this dataset to benchmark CycloNovo. We considered a cyclopeptide/spectrum as correctly sequenced if the sequence of the cyclopeptide appeared among reconstructions with three highest-scores. CycloNovo recognized 45 spectra in the CYCLOLIBRARY dataset as cyclospectra and correctly sequenced 38 of these cyclospectra (see Supplementary Note "CycloNovo analysis of the CYCLOLIBRARY dataset").
Analyzing the S.VULGARIS dataset. 23 recognized cyclospectra in this dataset correspond to twelve distinct cyclopeptides. CycloNovo sequenced ten of them with Pvalues below 10 -15 ( Table 2 ). Nine of ten reconstructed cyclopeptides match the assembled transcriptome. One reconstructed cyclopeptide (with the highest-scoring reconstruction AFLLADV and score 22), does not match the assembled transcriptome but a suboptimal ALFLGLD reconstruction with score 20 does (see Supplementary Note "Cyclopeptide-encoding transcripts in the S.VULGARIS dataset").
The ten reconstructed cyclopeptides (nine highest-scoring reconstruction and one suboptimal reconstruction) match 11 transcripts (some transcripts encode multiple cyclopeptides and some cyclopeptides are encoded by multiple transcripts) that belong to cyclopeptide-encoding PawS1-Like genes in various Asteraceae species 22, 24 . While three out of eleven identified PawL1 ORFs and the four cyclopeptides encoded by them (PLP-12 through PLP-15) have been extensively analyzed in recent studies 22, 24 Table 2 . Cyclopeptides reconstructed in the S.VULGARIS dataset. Ten reconstructed cyclopeptides (highlighted in yellow) along with their flanking sequences in transcripts translated into amino acids. For each of these cyclopeptides (reconstructed with P-values below 10 -15 ), we selected one representative spectrum with the highest score. The conserved flanking amino acids in the transcripts on the left and right sides of the highlighted cyclopeptides (preceding and succeeding motifs) are shown in red and green, respectively. For nine out of ten cyclopeptides, the reconstruction with the highest score matches one of the transcripts. For the cyclopeptide with mass 730.41 (highlighted in pink), the highest scoring reconstruction AFLLADV (score 22), does not match the assembled transcriptome but a suboptimal ALFLGLD reconstruction (score 20) does. The novel cyclopeptides discovered by CycloNovo are shown with bold IDs and named PLP-47 through PLP-52. For this dataset we used the error threshold ε=0.015 Da as recommended in Fisher et al 24 .
Analyzing the HUMANSTOOL dataset. The de novo reconstructions corresponding to the four spectra forming the spectral network. For each cyclopeptide, the cyclic sequence of the highest-scoring reconstruction along with their scores, the number of reconstructions with scores larger or equal to the PSM score (column "#reconstructions with score ≥ PSM score"), and P-values are listed. The "dates" column shows the dates when the corresponding samples were taken. Note that the cyclopeptides in this cyclofamily appear on the same dates. (Bottom) The annotated spectra of the four cyclopeptides based on the CycloNovo reconstructions.
The Dereplicator search of all 703 cyclospectra in the HUMANSTOOL dataset against PNPDatabase resulted in a single hit and identified a cyclic lipopeptide massetolide F 35 with P-value 7.5×10 -22 . As this compound includes lipid chains not included in the set of cyclopeptidic amino acids, CycloNovo was not able to generate its full-length reconstructions, but correctly reconstructed its partial amino acid sequence (see Supplementary Note "Cyclopeptides in the HUMANSTOOL dataset.") Massetolides are non-ribosomal lipopeptides produced by Pseudomonas fluoresences, an indigenous member of human and plant microbiota 36, 37 . Analysis of the metagenome assembly of reads paired with the HUMANSTOOL dataset confirmed that P. fluoresences is present in the stool samples where massetolide F was detected. Therefore, massetolide F most likely originated from P. fluoresences in the human microbiome (see Supplementary Note "Cyclopeptides in the HUMANSTOOL dataset" for information about the assemblies).
Analyzing the GNPS dataset. We analyzed all cyclospectra in the GNPS dataset using MS-Cluster 28 and SpecNets 38 with the goal of estimating the number of still unknown cyclopeptides and cyclofamilies originating from spectra already deposited into GNPS. To provide a conservative estimate for the number of cyclopeptides and cyclofamilies, we limited the analysis to clusters with at least three spectra. 12,004 cyclospectra in the GNPS dataset originated from 512 cyclopeptides and 213 cyclofamilies. Dereplicator search of these cyclospectra against CyclopeptideDatabase identified only 67 cyclopeptides from 37 cyclofamilies (see Supplementary Note "Cyclopeptides in the GNPS dataset"). For each putative cyclopeptide, we selected a representative spectrum with the highest k-merScore, resulting in 512 spectra corresponding to the 512 cyclopeptides. CycloNovo de novo sequenced 94 cyclopeptides with P-values below 10 -15 in this set of 512 cyclospectra (see Supplementary File).
Comparing CycloNovo and Dereplicator. Figure 4 compares the number of distinct cyclopeptides, including some branch-cyclic peptides, (see Supplementary Note "Cyclopeptides in the HUMANSTOOL dataset") and cyclofamilies revealed by CycloNovo and identified by Dereplicator in searches against the PNPDatabase. As Figure 4 illustrates, even for the extensively studied phyla of Cyanobacteria and Pseudomonas, only a small fraction of cyclopeptides and cyclofamilies revealed by CycloNovo are currently known. Moreover, CycloNovo revealed many novel cyclopeptides in known cyclofamilies. For example, CycloNovo reconstructed six novel variants of surugamide by analyzing the GNPSACTI dataset and revealed the widespread proliferation of the recently described A-domain skipping phenomenon 5, 39 , suggesting that it is more prevalent than was previously thought (each A-domain encodes a single amino acid in an NRP according to non-ribosomal code). Genome mining efforts typically rule out such events due to the consecutive arrangements of A-domains in NRP synthetases (see Supplementary Note "Surugamide spectral network."). 
DISCUSSION
Although the advent of the GNPS molecular network has created a new resource for natural product discovery, there exists a large body of still unknown bioactive compounds represented by various spectra in the GNPS network 4 (less than one percent of GNPS spectra have been identified so far). As the existing database search approaches are limited to identifying known cyclopeptides and their variants, de novo cyclopeptide sequencing is needed to reveal the "dark matter of cyclopeptidomics."
Charlop-Powers et al. 40 , recently demonstrated that New York urban parks (rather than exotic areas like rainforests or coral reefs) represent an untapped resource for discovery of clinically important non-ribosomal peptides. This surprising discovery illustrated the still unexplored biosynthetic potential of environmental metagenomes but has not revealed the chemical compounds that these metagenomes encode. As Nothias et al. 41 , wrote in the follow-up commentary Antibiotic discovery is a walk in the park, CharlopPowers et al., revealed the potential for discovering antibiotics in our backyards but did not answer the question what these molecules are and whether they are actually produced by the microbes. To address these questions, we analyzed the GNPS molecular network (our "digital version" of the New York Central Park that contains mass spectra from many environmental samples) and demonstrated that it contains spectra that originated from hundreds of still unknown cyclopeptides.
Only 81 out of 1,257 known cyclopeptides (42 out of 387 known cyclofamilies) have been identified in the GNPS network 5 . CycloNovo revealed over 400 unknown cyclopeptides from 176 novel cyclofamilies by analyzing only ≈51 million GNPS spectra, illustrating that the currently known cyclopeptides represent just a small fraction of cyclopeptides whose spectra have been already deposited into the GNPS network. CycloNovo correctly sequenced many known cyclopeptides in a blind mode and reconstructed many novel cyclopeptides that were validated using transcriptomics data.
Our analysis of the HUMANSTOOL dataset demonstrates that numerous bioactive cyclopeptides from consumed plants remain stable throughout the proteolytic, absorptive and microbial ecosystem provided by the gastrointestinal system and thus interact with human microbiome. It also found cyclospectra originating from the branch cyclic peptide massetolide produced by an indigenous member of the human microbiota and confirmed by metagenomics analysis. In addition, it revealed a large number of still unknown cyclopeptides in the human gut that are either a part of the human diet or are products of the human gut microbiome.
The cyclolinopeptides constitutes the largest identified component of the spectral network of all cyclospectra in the HUMANSTOOL dataset. Controlled diets have demonstrated beneficial effects of flaxseed consumption 32 and revealed that flaxseed is an effective chemo-preventive agent 42 . However, it remains unknown how flaxseed cyclopeptides affect the human microbiome. Previous studies of flaxseed focused on α-linolenic acid 43 and other bioactive compounds 44 affecting the digestive system. However, none of the flaxseed studies have identified what specific flaxseed ingredients are associated with the observed biological outcomes. As discussed in Shim et al. 43 , attributing a certain bioactivity to specific flaxseed compounds is a difficult task as multiple compounds are present in various flaxseed fractions.
It is remarkable that cyclolinopeptides remain stable in a proteolytic environment of the human gut and are not degraded. Although the immunosuppressive potential of cyclolinopeptides was established two decades ago 32 , little was known about their antimicrobial potential. Recent studies demonstrated significant antimicrobial activities of flaxseed, but it remains unclear which specific compounds are responsible for these activities 45 . As our analysis revealed that cyclolinopeptides survive the human digestive tract, we propose that the antimicrobial activities of flaxseeds might be caused by cyclolinopeptides, complementing their known anti-fungal 46 and anti-malarial 47 activities. Finding antimicrobial cyclopeptides in human stool raises the question of how these bioactive antimicrobial cyclopeptides might affect the human microbiome.
METHODS
Spectral convolution. We represent each spectrum Spectrum={s1, …, sn} as its spectral diagram, the set of n×(n-1)/2 2-dimensional points (si, sj) for 1 ≤ i <j ≤ n. Given a mass a, the convolution of Spectrum with offset a (denoted convolution(Spectrum, a)) is equivalently defined as the number of points in the diagonal (45°) band y ≈ x+a in the spectral diagram. Figure 5 presents the spectral diagram of TheoreticalSpectrum(AGCD) and reveals that bands corresponding to its amino acids (71, 57, 103, and 115 Da) are the most populous (contain a large number of points as compared to other bands), i.e., convolution(Spectrum,a) is high when a is the mass of amino acids A, G, C, or D. For example, TheoreticalSpectrum(AGCD) includes five pairs of fragment masses ((G,AG), (D,AD), (AGC,GC), (CD,CDA), and (GCD,AGCD)) that are located on the "blue" diagonal y = x+mass(A) in Figure 5 .
The spectral diagrams for TheoreticalSpectrum(Surugamide) and experimental SpectrumSurugamide highlight four populous diagonal bands y ≈ x+a, where a is the mass of one of four amino acids in surugamide with integer masses 71, 113, 128, and 147 (Supplementary Note "Analyzing spectral convolution.") These populous bands in the spectral diagram reveal the masses of amino acids in an unknown cyclopeptide that gave rise to an experimental spectrum. Figure 5 lists high-multiplicity clusters for SpectrumSurugamide (see Supplementary Note "Analyzing spectral convolution") and shows that many of them have masses that are similar to the masses of amino acids in surugamide. Since populous diagonals (highmultiplicity clusters) in the spectral diagram reveal amino acids in the unknown cyclopeptide that gave rise to an experimental spectrum, we use them to generate the set of putative amino acids 18 .
Recognizing cyclospectra. A cluster in the spectral convolution is called frequent if its multiplicity exceeds the cluster multiplicity threshold (the default threshold for SpectrumSurugamide is 7). CycloNovo classifies a spectrum as a cyclospectrum if the number of frequent cyclopeptidic clusters in its spectral convolution is at least minNumberFrequentClusters (the default value minNumberFrequentClusters=2). Since there exist two frequent cyclopeptidic clusters for SpectrumSurugamide (corresponding to amino acids I/L and K), it is classified as cyclopeptidic ( Figure 5 ). In addition to SpectrumSurugamide, out of 938 spectra passing the preprocessing step in the small spectral dataset for Streptomyces CNQ329 that contains SpectrumSurugamide, CycloNovo recognized only one cyclospectrum, also originated from surugamide. See Supplementary Note "Distinguishing cyclospectra from spectra of linear peptides and polymers" for selecting CycloNovo parameters.
Estimating the number of distinct cyclopeptides and cyclofamilies. Spectral datasets often contain multiple spectra originating from the same compound. CycloNovo clusters similar cyclospectra using MS-Cluster 28 and estimates for the number of distinct cyclopeptides as the number of constructed clusters. It further constructs the spectral network of cyclospectra using SpecNets 3 and estimates for the number of distinct cyclofamilies as the number of connected components in this network.
Inorg. Chem. 92, 2805-2809 (1959 
Supplementary Note: Surugamide spectral network
Supplementary Figure S1 shows a connected component in the spectral network containing known and novel surugamide variants (spectral dataset GNPSACTI generated from samples collected from various Actinomyces species).
Supplementary Figure S1 . A connected component in the spectral network that contains various surugamide variants. Each node in the network is labeled by the precursor mass of a spectrum and each edge connects spectral pairs that reveal related cyclopeptides. The five green nodes are the known surugamide variants 1 . The pink nodes represent unknown cyclopeptides. The spectral network was constructed based on all cyclospectra in the GNPSACTI dataset.
Supplementary Figure S2 shows a subgraph of the spectral network shown in Supplementary Figure S1 that includes only known surugamides and six novel variants reconstructed by CycloNovo. Supplementary Figure S3 illustrates that five of these novel variants differ from known surugamides by deletions of some amino acids. add an amino acid to a cyclopeptide. (c) De novo reconstructions of the novel surugamide variants. The column 'PSM score/highest score' shows the score of the cyclopeptide and the highest score observed for that spectrum among all CycloNovo reconstructions. The "P-value" column presents the P-value of the PSM (for each cyclopeptide, the spectrum that yielded the lowest P-value is reflected). The column "#reconstructions with score ≥ PSM score" shows the number of reconstructions with score greater or equal to the PSM score. The column "reconstruction with the highest score" shows a highest-scoring reconstruction for the cases when the PSM score is below the highest score. The number of spectra corresponding to each novel surugamide variant in the five GNPS datasets are presented in the columns '78604', '78787', '78936', '78937', and '79516', representing the GNPS sub-datasets MSV000078604, MSV000078787, MSV000078936, MSV000078937, and MSV000079516, respectively. Finding the same surugamide variants in different studies makes it unlikely that they represent artifacts. (d) Annotated spectra of six novel surugamide variants. 
Supplementary Note: An example of the de Bruijn graph

Supplementary Note: Preprocessing spectra
Similar to pre-processing practices in proteomics 3 , CycloNovo filters out low-intensity peaks in each spectrum by retaining at most 5 peaks with the highest intensities in each 50 Da window. CycloNovo further filters out all peaks that are less than 0.05 Da apart from another peak with higher intensity. It further removes spectra with a small number of peaks (less than 20) and spectra with a small precursor mass (less than 500 Da). We subtract the mass of a hydrogen atom from all masses in the spectrum (for simplicity, we assume that each ion is protonated with a single proton). Supplementary Table S1 . The default values of CycloNovo parameters along with the command-line arguments to specify their values. The parameters introduced in the main text are shown in green rows and the parameters introduced in the Supplementary Note "Distinguishing cyclospectra from spectra of linear peptides and polymers" are shown in pink rows. For all datasets in this paper, all cyclospectra were recognized with the default parameters = 0.007 and = −1, except for cyclospectra in the GNPS datasets that were recognized with even more conservative parameters = 0.008 and = 0.
Supplementary Note: CycloNovo parameters
Supplementary Note: Distinguishing cyclospectra from spectra of linear peptides and polymers
The challenge of distinguishing cyclospectra from spectra of linear peptides and polymers. Fragmentation of linear peptides typically results in prefix (e.g., b-ions) and suffix (e.g., y-ions) ions and rarely generates internal ions. However, spectra of some linear peptides feature a substantial number of internal ions, leading to a possibility to erroneously classify them as cyclospectra. Another source of a potential misclassification of some spectra as cyclospectra are polymers that represent a common source of contamination in mass spectral datasets. Since polymers are made up of repeated units, the spectral convolution of a polymer spectrum typically has high-multiplicity clusters (for clusters corresponding to masses of the repeat units). In some cases, the adducts of these repeat units form high multiplicity clusters with masses equal to the masses of a cyclopeptidic amino acid, triggering a possibility to misclassify a polymer spectrum as a cyclospectrum.
LINEARLIBRARY and POLYMERLIBRARY datasets. To ensure that CycloNovo does not misclassify spectra of linear peptides and polymers as cyclospectra, we analyzed two spectral datasets described below:
• LINEARLIBRARY is a set of 105,871 Collision-Induced Dissociation (CID) tandem mass spectra of distinct linear peptides from the Massive KnowledgeBased spectral library 4 of linear peptides distilled from all human proteomics data in the MassIVE database.
• POLYMERLIBARY is a set of 448 tandem spectra generated from polyethylene glycol (MSV000081544).
These spectral datasets have spectra with the precursor masses varying between 500 Da and 2000 Da and the charges at most 2.
Additional tests for recognizing cyclospectra. To distinguish cyclospectra from spectra of linear peptides and polymers, CycloNovo only classifies a spectrum as cyclopeptidic if it passes additional tests described below.
• High multiplicity cyclopeptidic clusters test (distinguishing cyclospectra from spectra of linear peptides). As described in the main text, CycloNovo first selects a spectrum for further analysis if its spectral convolution has at least minNumberFrequentClusters frequent cyclopeptidic clusters, i.e., clusters with multiplicities exceeding the cluster multiplicity threshold. Since the cluster multiplicities typically increase with the increase in the length of a peptide, this threshold increases with the increase in the peptide mass. We thus defined the cluster multiplicity threshold as α×precursorMass+β (see below for selecting parameters α and β).
• Polymer test (distinguishing cyclospectra from polymer spectra). For each cyclospectrum Spectrum, CycloNovo analyzes clusters with masses of repeat units observed in background contamination from polyethylene glycol, NaCl, polypropylene glycol, and trimethylsiloxane (44.03, 57.96, 58.04, and 72.04 Da, respectively). We refer to these masses as polymeric units 5 and refer to clusters with masses equal to polymeric units as polymer-clusters. CycloNovo classifies a spectrum as polymeric if there exist at least minNumberFrequentClusters polymer-clusters with multiplicities at least the cluster multiplicity threshold. Polymeric spectra are filtered out from the set of found cyclospectra.
• cycloIntensity test. For each cyclospectrum, CycloNovo considers all frequent cyclopeptidic clusters. For each such cluster of mass a, we consider all pairs of masses x and y in the spectrum contributing to this cluster, i.e., satisfying the condition y≈x+a. The cyclointensity of the spectrum, referred to as cycloIntensity, is defined as the total intensity of all such peaks (across all frequent cyclopeptidic clusters) divided by the total intensity of all peaks in Spectrum. Spectra with cyclointensity below the cycloiIntensity threshold are filtered out.
• k-merScore test. CycloNovo computes the k-merScore, the score of the highestscoring k-mer that contributes to the de Bruijn graph of the spectrum and filters out cyclospectra with k-merScore below the k-merScore threshold.
Selecting thresholds for recognizing cyclospectra. To select the default value of cluster multiplicity threshold=α×precursorMass+β, we varied parameters α (from 0.005 to 0.02) and β (from -5 to +5) and analyzed all found cyclospectra in the CYCLOLIBRARY, LINEARLIBRARY, and POLYMERLIBARY datasets (Supplementary Figure S5) . Despite its smaller size, CYCLOLIBRARY is the only dataset where CycloNovo recognizes cyclospectra for all analyzed values of α and β. Since α=0.07 and β=-1 yielded the largest number of recognized cyclospectra in CYCLOLIBRARY (46 out of 81) and no cyclospectra in the LINEARLIBRARY and POLYMERLIBRARY datasets (Supplementary Figure S5) , we selected these values as the default parameters.
Supplementary Figure S5 . Number of spectra passing both the "high multiplicity cyclopeptidic cluster" and the "polymer" tests in the CYCLOLIBRARY, LINERALIBRARY, and POLYMERLiBRARY datasets (for various values of parameters α and β).
Supplementary Figure S6 presents the values of cycloIntensity and k-merScore for each spectrum in the CYCLOLIBRARY, LINEARLIBRARY, and POLYMERLIBRARY datasets and reveals a separation between the former and the two latter datasets with respect to these two parameters. CycloNovo thus classifies a spectrum as a cyclospectrum if its cycloIntensity exceeds the cycloIntensity threshold (60%) and its k-merScore exceeds the k-merScore threshold (5) . 45 spectra in the CYCLOLIBRARY datasets, that pass all four tests described above, are classified as cyclospectra.
Supplementary Figure S6 . Values of cycloIntensity and k-merScore for all spectra in the CYCLOLIBRARY, POLYMERS, and LINEARLIBRARY datasets (for k=5).
We also investigated how CycloNovo's ability to recognize a cyclospectrum is affected by the fragmentation quality of the corresponding PSM (measured by the P-value of this PSM). For each spectrum in the CYCLOLIBRARY dataset, we identified the minimum value of the parameter α that leads to classifying this spectrum as cyclopeptidic (for β=-1). Supplementary Figure S7 illustrates that well-fragmented spectra can be recognized even with more restrictive threshold values (larger values of α).
Supplementary Figure S7 . Dependence between the P-value of each spectrum in the CYCLOLIBRARY dataset and the minimum value of the parameter α that leads to classifying this spectrum as a cyclospectrum (for = − ). Each point represents a spectrum in the CYCLOLIBRARY dataset. The x-axis shows the P-value of the PSM for that spectrum and the y-axis shows the minimum value of the parameter α that leads to classifying this spectrum as a cyclospectrum. The points corresponding to cyclospectra recognized with the default parameter α=0.07 are shown in red. 
Supplementary Note: Cyclopeptidic amino acids
Supplementary Note: Analyzing spectral convolution
Supplementary Figure S8 illustrates that each amino acid in surugamide results in a populous diagonal in the spectral diagram of SpectrumSurugamide. For each constructed cluster (diagonal band in the spectral diagram), we consider all pairs of masses in Spectrum that contributed to this cluster and form a band as the set of these k pairs.
We define the cluster diameter as the difference between its maximum and minimum elements. Supplementary Figure S9 presents the band for the cluster with multiplicity 8 and mass 128.09 (diameter 0.03) in the spectral convolution of SpectrumSurugamide and reveals that the 8 elements of this band can be partitioned into 7 groups of closely located points. We are interested in the number of such groups (rather than the raw cluster multiplicities) since experimental spectra often contain satellite masses resulting from neutral losses and isotopic peaks. Since satellite masses artificially inflate cluster multiplicities, there is a need to reduce biases caused by these masses. We thus define the set of common satellite offsets (1 Da (H), 18 Da (H2O), 17 Da (NH 3 ), and 28 Da (CO)) and perform additional single linkage clustering in each populous band by combining pairs of masses in a single cluster if both their x-coordinates and y-coordinates differ by a satellite offset. We redefine the concept of cluster multiplicity as the number of the resulting clusters in the band (Supplementary  Table S3 ). 
Supplementary Note: CycloNovo running time
CycloNovo recognizes cyclospectra by constructing their spectral convolutions (O(n 2 ) running time for a spectrum with n peaks) and further sequences all found cyclospectra. Using a single 2.5GHz processor, CycloNovo recognized all cyclospectra in the HUMANSTOOL and GNPS datasets in ≈35 minutes and ≈31 hours, respectively. The sequencing step is only applied to a small fraction of all spectra in spectral datasets, e.g., CycloNovo recognizes only ≈0.05% of all spectra in the GNPS dataset as cyclospectra. The running time for the sequencing step varies widely between spectra and depends on the number of putative amino acid compositions, the number of putative kmers, and the number feasible cycles in the de Bruijn graphs.
We were not able to benchmark CycloNovo against CYCLONE 7 since CYCLONE failed to reconstruct most spectra in the CYCLOLIBRARY dataset. For example, CycloNovo took ≈3 seconds to sequence SpectrumSurugamide. In contrast, CYCLONE 7 failed to sequence SpectrumSurugamide and was not even able to infer alanine and lysine as amino acids in suragamide.
We thus compared CycloNovo with a brute force sequencing algorithm by generating and scoring all possible permutations of all amino acid compositions resulting from the putative amino acids for SpectrumSurugamide. The brute-force approach took ≈27 seconds to sequence SpectrumSurugamide as the highest scoring reconstruction among all 113 generated cyclopeptides. In a more difficult example, we analyzed the spectrum with precursor mass 899.36 and reconstructed the orbitide FVDTTGYD in the S.VULGARIS dataset ( Table  2) . CycloNovo sequenced this spectrum in 56 seconds while the brute force approach took 58 minutes. For this spectrum, there exist 321 putative amino acid compositions yielding over 400,000 candidate sequences. Since the majority of those ~400,000 sequences do not produce high-scoring 5-mers, they yield the relatively small de Bruijn graphs and hence small numbers of feasible cycles and candidate cyclopeptides. By only exploring the feasible cycles in the de Bruijn graphs, CycloNovo reduced the number of candidate sequences to 2,491.
These examples illustrate that the running time of CycloNovo varies by orders of magnitude depending on analyzed cyclospectra. By only exploring the sequences spelled by the feasible cycles in the de Bruijn graphs, CycloNovo greatly reduces the search space compared to the brute force approach. For example, the brute force approach failed after 1000 hours on just two cyclospectra from the CYCLOLIBRARY dataset, while the de Bruijn graph approach finished analysis of all spectra in this library in ≈48 hours. Supplementary Note "CycloNovo analysis of the CYCLOLIBRARY dataset" lists all CycloNovo reconstructions for this dataset. CycloNovo analysis of the HUMANSTOOL and GNPS datasets took ~34 and ~149 hours, respectively.
Supplementary Note: Information about spectral datasets
Information about CyclopeptideDatabase. The PNPDatabase 8 combines all known peptidic natural products from various databases. Many peptides in this database are lipopeptides containing a lipid chain, e.g., surfactin is a cyclopeptide containing a fatty acid side chain connected to a fully peptidic part via a peptide bond.
We classify a peptide in the PNPdatabase as a cyclopeptide if its backbone could be represented as a circular graph (cycle) with nodes corresponding to either a single amino acid or a single lipid tail (i.e. monomers) and edges corresponding to the amide bonds in the peptide structure. 1,257 out of 5,021 peptides in the PNPDatabase represent cyclopeptides and form CyclopeptideDatabase (note that the CyclopeptideDatabase database contains lipopeptides).
Information about the CYCLOLIBRARY dataset. We searched ~130 million GNPS spectra against the CyclopeptideDatabase using Dereplicator 1 and identified 81 distinct cyclopeptides (41 cyclofamilies) corresponding to PSMs with FDR=0% and P-value below 10 -15 . For each identified cyclopeptide, we selected the PSM with the minimum Pvalue (among all PSMs identified for this cyclopeptide), resulting in a set of 81 PSMs and hence created a spectral dataset CYCLOLIBRARY with 81 spectra (Table S4) . CYCLOLIBRARY includes only 13 cyclopeptides (6 cyclofamilies) that are made up entirely of cyclopeptidic amino acids (Table S4) . 34 peptides (25 cyclofamilies) in the CYCLOLIBRARY dataset contain lipid tails and 34 peptides (14 cyclofamilies) contain non-cyclopeptidic amino acids. Supplementary Table S4 . Cyclopeptides in the CYCLOLIBRARY dataset. The peptides that gave rise to 81 spectra in the CYCLOLIBRARY dataset with their corresponding peptide mass, P-value, the GNPS ID of the dataset a spectrum belongs to, k-merScore, and cycloIntensity. The column "compound type"
specifies whether the compound is fully peptidic or represents a lipopeptide. The blue rows show the 13 cyclopeptides that are made up entirely of cyclopeptidic amino acids.
Information about the GNPS dataset. The GNPS dataset is formed by 40 MassIVE datasets that were selected from 120 datasets analyzed in Gurevich et al. 8 to exclude potentially miscalibrated spectral datasets. Since miscalibrated datasets typically do not result in any cyclopeptide identifications, we searched each of these 120 datasets with Dereplicator and excluded datasets that did not result in any identifications (with 0% FDR and P-value below 10 -15 ) from further analysis, leaving us with 40 datasets (Supplementary Table S5 Supplementary Table S5 . Information about the GNPS dataset. The last row shows the total number of spectra and unique cyclopeptides/cyclofamiles across all datasets. The datasets marked in red, blue, and green form GNPSCYANO, GNPSPSEUDO, and GNPSACTI subsets of the GNPS dataset, respectively.
Supplementary Note: CycloNovo analysis of the CYCLOLIBRARY dataset
CycloNovo recognized 45 out of 81 spectra in the CYCLOLIBRARY dataset as cyclospectra. It classified 12 out of 13 cyclopeptides built from cyclopeptidic amino acids as cyclospectra and de novo sequenced them with one of the top three highest scores.
CycloNovo is unable to sequence most spectra in the CYCLOLIBRARY dataset since 68 of them originated from lipopeptides or peptides containing non-cyclopeptidic amino acids. To evaluate how CycloNovo performs on 45 cyclospectra in this dataset, we extended the set of cyclopeptidic amino acids to include the mass of the lipid chain and/or the masses of non-cyclopeptidic amino acids for each spectrum. Using this admittedly imperfect benchmarking approach, CycloNovo sequenced 22 of 45 cyclospectra as a highest-scoring de novo reconstructions and an additional 16 spectra with one of the three highest scores. Supplementary Table S6 lists the highest-scoring reconstruction for these spectra and illustrates that the highest-scoring reconstruction is similar to the correct amino acid sequence for all these spectra. Supplementary Table S6. 38 cyclopeptides reconstructed by CycloNovo from 45 cyclospectra in the CYCLOLIBRARY dataset. The PSM score represents the score of the PSM in the CYCLOLIBRARY dataset. The "max score" represents the score of the top-scoring reconstruction. For 22 cyclopeptides, the correct sequence of the cyclopeptide has the highest-scoring reconstruction. For the remaining 16 cyclopeptides, a highest-scoring reconstruction is listed below the correct sequence of the cyclopeptide in blue (differently arranged amino acid masses in the reconstructed cyclopeptide are shown in bold blue). Only in one case (cyclosporin C), CycloNovo predicted the wrong amino acids (shown in red) for the topscoring reconstruction. CycloNovo failed to sequences 45-38=7 cyclospectra in the CYCLOLIBRARY dataset since it was not able to predict all their amino acids.
Supplementary Note: Cyclopeptide-encoding transcripts in the S.VULGARIS dataset
Supplementary 
Sv_PawL1b
AKLIVVVFAFAVIVAFAEVSAYKTTITTTTVEDNFVGGTSFDRLSENFMYGTPVDRL SDNRGSQKQCHRQIP
Sv_PawL1c
AKLIVVVFAFAVIVAFAEVSAYKTTITTTTVEDNTFGVVIADRLSDNFVDTTGYDRL SDNRGSQKQCHRQIP
Sv_PawL1d
ITTVEDNALVVGLDGLDNPITTTVEDNYFAGLIDGLDNPITTTVEDNGVFLGLDGLD NPSGSTYQCRRQIQGQQLNHCQMHIIQQGRSLVE
Sv_PawL1e
FVAIVAFSEQVSAYKTTIPTTVEDNALLVALDGLDNGFHGTFDGLDNGFHGTFDGLD NPSGSTYQCRRQIQ*
Sv_PawL1f
TTVEDNALFLGLDGLDNPSGSTYQCRRQIQGQQLNHCQMHITQQGRSLMENPRQQQL LQMCCNQLRQVEEECQCE*
Sv_PawL1g
ITTTVEDNALVVGLDGLDNPITTTVEDNFVGGVIDGLDNFVGGVIDGLDNPSGSTYK CRRQIQGQQLNHCQMHITQQGRSLVE
Sv_PawL1h
MTKVSAIVVLAFVAIVAFSEQVSAYKTTITTPVEDNAIFLGVDGLDNPI*
Sv_PawL1i
LDGLDNALLGIADGLDNPSGSTYQCRMQIQGQQLNHCQMHIIQQGRSLVENPRQQQQ LQMCCNQLR*
Sv_PawL1j
SEQVSAYKTTITTTVEDNAIFGVVDGLDNPSGSTYQCRKQIQGQQ*
Sv_PawL1k
AIVAFSEQVSAYKTTITTTVEDNAIFLGVDGLDNPITTTVEDNGVSDFFDDGLDKPS GSTYQCRRQIQGQQLNHCQMHISQQGRSLVENPRQQQQLQM*
Sv_PawL1l
FVAIVAFSEQVSAYKTTITTPVEDNGVVVGFDGLDNPSGSTYQCRKQIQGQQ*
Supplementary Table S7 . ORFs in the cyclopeptide-encoding transcripts. All identified ORFs originate from various PawS1-Like genes. The sequences are color-coded based on the subunits they belong to: endoplasmic reticulum signal sequence (pink), the reconstructed cyclopeptide (blue), 2S albumin small subunit (lime green), and 2S albumin large subunit (orange). While the first three sequences (Sv_PawL1b, Sv_PawL1c, and Sv_PawL1d) are known PawS1-Like genes in S. vulgaris, the other eight sequences (named Sv_PawL1e through Sv_PawL1l) are novel PawS1-Like genes that were identified by searching for novel cyclopeptides.
Supplementary Figure S11 shows cyclospectra in the S.VULGARIS dataset, annotated using their CycloNovo reconstructions.
Supplementary Figure S11 . Annotated cyclospectra of the ten reconstructed cyclopeptides in the S.VULGARIS dataset. The x-axis shows the m/z ratios and the y-axis shows the percentage of the peak intensity compared to the intensity of the largest peak in that spectrum. Cyclospectra of branch-cyclic peptides in the HUMANSTOOL dataset. We classify a peptide as branch-cyclic if its backbone includes a cycle (with all monomers connected via amide bonds) and a side chain that includes at least one additional amide bond not included in the cycle. Although CycloNovo classify spectra of some branch cyclic peptides as cyclospectra (see Supplementary Note "Information about spectral datasets"), it is unable to de novo sequence them. Nevertheless, CycloNovo provides information about substrings of branch-cyclic peptides made of cyclopeptidic amino acids. For example, CycloNovo classified the spectrum of massetolide F in the HUMANSTOOL dataset as a cyclospectrum. The lipopetide massetolide F consists of the cycle TILSLSLV and a branch EL (along with a fatty acid chain tail with nominal mass 171 Da) connected to the cycle via an amide bond between T and E. We represent this branch cyclic peptides as a concatenate between the sequence of nominal masses of the cyclic and branch region separated by "*" sign, i.e., massetolide F is represented as 100, 113, 87, 113, 87, 113, 99 * 129, 113, 171. CycloNovo found five cyclopeptidic amino acids in massetolide F (S, I, L, V, T, and E) and missed the lipid chain (171 Da).
Assembly of the human stool sample where massetolide F was detected. We used metaSPAdes 10 to assemble the metagenomic dataset, generated from the stool sample (dated by 6/16/2014) where massetolide F was detected, This dataset includes 34.5 million paired reads which are assembled into 81 thousand scaffolds of lengths longer than 500 bp amounting to 407 Mb total assembly length.
Supplementary Note: Cyclopeptides in the GNPS dataset
Supplementary Figure S13 shows the number of identified cyclopeptides across all GNPS sub-datasets. Supplementary Figure S14 shows the number of cyclopeptides and cyclofamilies that gave rise to cyclospectra found by CycloNovo across all GNPS subdatasets.
Supplementary Figure S13 . Number of cyclopeptides identified by Dereplicator across all GNPS subdataset. Dereplicator identified 81 cyclopeptides in the GNPS dataset. Since some cyclopeptides are identified in multiple sub-datasets, the total numbers of identified cyclopeptides across all GNPS subdatasets (180) exceeds 81. The green (blue) part of each bar represent spectra that were (were not) classified by CycloNovo as cyclospectra.
